Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 1H | First half of a calendar year |
| 2q8 | Aflibercept 2 mg every 8 weeks |
| 8q12 | Aflibercept 8 mg every 12 weeks |
| 8q16 | Aflibercept 8 mg every 16 weeks |
| AAO | American Academy of Ophthalmology |
| ADL | Activities of daily living |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| AMD | Age-related macular degeneration |
| ANCOVA | Analysis of covariance |
| API | Active pharmaceutical ingredient |
| AREDS | Age-Related Eye Disease Study |
| AREDS2 | Age-Related Eye Disease Study 2 |
| ASP | Average sales price |
| ATP | Adenosine triphosphate |
| BCVA | Best-corrected visual acuity |
| BIM | Budget impact model |
| BLVA | Baseline visual acuity |
| CATT | Comparison of Age-Related Macular Degeneration Treatments Trials |
| CBS | Charles Bonnet syndrome |
| CDC | Centers for Disease Control and Prevention |
| CES-D-10 | Center for Epidemiologic Studies Depression Scale, 10-item version |
| CFP | Color fundus photography |
| cGMP | Current Good Manufacturing Practice |
| CI | Confidence interval |
| CMS | Centers for Medicare & Medicaid Services |
| CNV | Choroidal neovascularization |
| CONSORT | Consolidated Standards of Reporting Trials |
| CPAP | Continuous positive airway pressure |
| CPT | Current Procedural Terminology |
| CrI | Credible interval |
| CST | Central subfield thickness |
| CY | Calendar year |
| DALY | Disability-adjusted life-year |
| DFG | Aspartate-phenylalanine-glycine motif of the kinase activation loop |
| DME | Diabetic macular edema |
| DR | Diabetic retinopathy |
| DSMC | Data Safety Monitoring Committee |
| ECM | Extracellular matrix |
| EDTRS | Early Treatment Diabetic Retinopathy Study (spelling as printed in the registry record) |
| EMA | European Medicines Agency |
| ETDRS | Early Treatment Diabetic Retinopathy Study |
| EURETINA | European Society of Retina Specialists |
| FA | Fluorescein angiography |
| FAF | Fundus autofluorescence |
| FAS | Full analysis set |
| FDA | U.S. Food and Drug Administration |
| FSS | Federal Supply Schedule |
| GA | Geographic atrophy |
| GBD | Global Burden of Disease |
| H1 | First half of a calendar year |
| HbA1c | Glycated hemoglobin |
| HCPCS | Healthcare Common Procedure Coding System |
| HR | Hazard ratio |
| IC50 | Half-maximal inhibitory concentration |
| IL-6 | Interleukin 6 |
| IOI | Intraocular inflammation |
| IQR | Interquartile range |
| IRF | Intraretinal fluid |
| IRIS | Intelligent Research in Sight (American Academy of Ophthalmology registry) |
| IVT | Intravitreal |
| JAK1 | Janus kinase 1 |
| logMAR | Logarithm of the minimum angle of resolution |
| LTFU | Lost to follow-up |
| M1 | Entire effect of the active control assumed to be present in a non-inferiority study |
| M2 | Largest clinically acceptable difference of the test drug compared with the active control |
| MA | Medicare Advantage |
| MARINA | Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD |
| mcg | Micrograms |
| MedPAC | Medicare Payment Advisory Commission |
| MHI | Mental Health Index |
| mmHg | Millimeters of mercury |
| MMRM | Mixed model for repeated measures |
| MNV | Macular neovascularization |
| MOA | Mechanism of action |
| MSVI | Moderate or severe vision impairment |
| NA | Not available |
| nAMD | Neovascular age-related macular degeneration |
| NDA | New Drug Application |
| ng/mL | Nanograms per milliliter |
| NI | Non-inferiority |
| NICE | National Institute for Health and Care Excellence |
| NVAMD | Neovascular age-related macular degeneration |
| nvAMD | Neovascular age-related macular degeneration |
| NYHA | New York Heart Association (printed in the source as New York Hospital Association) |
| OCT | Optical coherence tomography |
| OCTA | Optical coherence tomography angiography |
| OR | Odds ratio |
| PA | Prior authorization |
| PCV | Polypoidal choroidal vasculopathy |
| PDGF | Platelet-derived growth factor |
| PDGFR | Platelet-derived growth factor receptor |
| PDS | Port delivery system |
| PDT | Photodynamic therapy |
| PFS | Physician Fee Schedule |
| pg/mL | Picograms per milliliter |
| PIGF | Placental growth factor |
| PRN | Pro re nata (as needed) |
| q24W | Every 24 weeks |
| Q4 | Fourth quarter |
| q6M | Every 6 months |
| q8W | Every 8 weeks |
| QALY | Quality-adjusted life-year |
| R&D | Research and development |
| REMS | Risk Evaluation and Mitigation Strategy |
| ROS | Reactive oxygen species |
| RPE | Retinal pigment epithelium |
| RPED | Retinal pigment epithelium detachment |
| RTK | Receptor tyrosine kinase |
| RWE | Real-world evidence |
| SAE | Serious adverse event |
| SD | Standard deviation |
| SD-OCT | Spectral-domain optical coherence tomography |
| SE | Snellen equivalent |
| sNDA | Supplemental New Drug Application |
| SRF | Subretinal fluid |
| T&E | Treat-and-extend |
| TEAE | Treatment-emergent adverse event |
| TIE2 | Tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (angiopoietin receptor) |
| TIR | Time in range |
| TKI | Tyrosine kinase inhibitor |
| TNF | Tumor necrosis factor |
| UI | Uncertainty interval |
| UK | United Kingdom |
| US | United States |
| USD | United States dollars |
| VA | Visual acuity; in manufacturer filings, U.S. Department of Veterans Affairs |
| VEGF | Vascular endothelial growth factor |
| VEGF-A | Vascular endothelial growth factor A |
| VEGF-B | Vascular endothelial growth factor B |
| VEGFR | Vascular endothelial growth factor receptor |
| VIEW | VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD |
| W | Week (as in W52 and W56) |
| wAMD | Wet age-related macular degeneration |
| WTP | Willingness to pay |
| µg | Micrograms |
| µm | Micrometers |